#1 Clinical Trials Search in Europe

Human Papillomavirus Type 58 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna

This article summarizes several clinical trials investigating the use of the 9-valent human papillomavirus (HPV) vaccine, also known as Gardasil 9, for preventing and treating various HPV-related conditions. The trials examine the vaccine’s efficacy, safety, and immunogenicity in different populations and scenarios, including extended dosing intervals, immunocompromised patients, and treatment of HPV-related lesions. These studies aim to optimize the use of the HPV vaccine and explore its potential therapeutic applications beyond standard preventive vaccination.

Table of Contents

What is the HPV Type 58 L1 Protein?

The Human Papillomavirus (HPV) Type 58 L1 Protein is one of the components in the 9-valent HPV vaccine, also known as Gardasil 9. This vaccine is designed to prevent infections and diseases caused by nine types of HPV, including type 58.[1]

HPV type 58 is considered a high-risk HPV type that can cause cervical cancer and other HPV-related cancers. The L1 protein is the major structural protein of the HPV virus that forms the outer shell or “capsid” of the virus particle.

How Does it Work?

The vaccine contains the L1 protein from HPV type 58 in the form of virus-like particles (VLPs). These VLPs are produced using recombinant DNA technology in yeast cells. They mimic the structure of the real virus but do not contain any genetic material, so they cannot cause an infection.[1]

When the vaccine is administered, these VLPs stimulate the immune system to produce antibodies against HPV type 58. If a person is later exposed to the real virus, their immune system can quickly recognize and neutralize it, preventing infection.

Current Clinical Trials

Several clinical trials are currently investigating the use of the 9-valent HPV vaccine, which includes the HPV Type 58 L1 protein component:

  • A study evaluating extended 2-dose regimens in 9-14 year old boys and girls compared to a standard 3-dose regimen in 16-26 year old women.[1]
  • A trial assessing the vaccine’s immunogenicity in immunocompromised children and adolescents.[2]
  • Research on the vaccine’s efficacy in preventing oral persistent HPV infection in adult males aged 20-45.[3]
  • A study on the effectiveness of the vaccine in women treated for vulvar high-grade squamous intraepithelial lesions (vHSIL).[4]
  • Trials evaluating the vaccine’s efficacy in women over 45 who have been treated for high-grade cervical lesions.[5]

Effectiveness and Safety

Clinical trials have shown that the 9-valent HPV vaccine, which includes the HPV Type 58 L1 protein, is highly effective in preventing infections and diseases caused by the targeted HPV types. The vaccine has demonstrated a good safety profile in various populations.[1]

Ongoing studies are assessing its effectiveness in different scenarios, such as extended dosing intervals, use in immunocompromised individuals, and prevention of oral HPV infections.

Who Can Receive This Vaccine?

The 9-valent HPV vaccine containing the HPV Type 58 L1 protein is approved for use in:

  • Girls and boys aged 9-14 years (2 or 3-dose schedule)
  • Adolescents and adults aged 15-45 years (3-dose schedule)

Some ongoing trials are also investigating its use in specific populations, such as immunocompromised individuals and older adults with a history of HPV-related lesions.[2]

How is it Administered?

The vaccine is typically administered as an intramuscular injection. The standard dosing schedule involves:

  • 2 doses (0 and 6-12 months) for individuals 9-14 years old
  • 3 doses (0, 2, and 6 months) for individuals 15 years and older

Some clinical trials are exploring extended dosing intervals to potentially reduce the number of doses needed while maintaining effectiveness.[1]

Potential Side Effects

Common side effects of the 9-valent HPV vaccine may include:

  • Pain, swelling, or redness at the injection site
  • Headache
  • Fever
  • Nausea
  • Dizziness

Serious allergic reactions are rare but possible. As with any vaccine, healthcare providers monitor for any adverse events following immunization.[3]

Conclusion

The HPV Type 58 L1 protein component of the 9-valent HPV vaccine plays a crucial role in preventing infections and diseases caused by HPV type 58. Ongoing clinical trials continue to explore its effectiveness in various populations and dosing schedules. As always, individuals should consult with their healthcare provider to determine if this vaccine is appropriate for them based on their age, health status, and risk factors.

Trial Focus Population Key Objectives Potential Outcomes
Extended dosing intervals Children and adolescents 9-14 years old Evaluate safety and immunogenicity of 2-dose regimens with extended intervals Potential for simplified vaccination schedule with maintained efficacy
Immunocompromised patients Immunocompromised children and adolescents Assess immunogenicity in various immunocompromised groups Understanding vaccine effectiveness in vulnerable populations
Oral HPV prevention Adult males 20-45 years old Evaluate efficacy in preventing oral persistent HPV infection Potential reduction in HPV-related oral cancers
Post-treatment of vulvar HSIL Women with vulvar high-grade squamous intraepithelial lesions Assess efficacy in preventing recurrence after treatment Improved management of vulvar HSIL and reduced recurrence rates
Post-treatment of cervical lesions Women over 45 with high-grade cervical lesions Evaluate impact on recurrence and HPV clearance after LEEP Enhanced post-surgical outcomes and potentially reduced follow-up requirements
Treatment of resistant warts Patients with difficult-to-treat palmar or plantar warts Assess efficacy in treating resistant warts Novel therapeutic approach for challenging HPV-related skin conditions

FAQ

  • What is the 9-valent HPV vaccine? The 9-valent HPV vaccine, also known as Gardasil 9, is a vaccine that protects against nine types of human papillomavirus (HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58). It is designed to prevent HPV-related diseases such as cervical, vulvar, vaginal, and anal cancers, as well as genital warts.
  • What populations are being studied in these clinical trials? The clinical trials are studying various populations, including children and adolescents aged 9-14 years, immunocompromised children and adolescents, adult males aged 20-45 years, women with vulvar high-grade squamous intraepithelial lesions (vHSIL), women over 45 with high-grade cervical lesions, and patients with difficult-to-treat palmar or plantar warts.
  • What are some of the main objectives of these trials? The main objectives of these trials include evaluating the safety and immunogenicity of extended dosing intervals, assessing the vaccine's efficacy in preventing oral persistent HPV infection in adult males, investigating its effectiveness in reducing recurrence of vulvar and cervical lesions after treatment, and exploring its potential in treating difficult-to-treat warts.
  • How is the vaccine administered in these trials? The vaccine is typically administered as an intramuscular injection. The dosing schedules vary between trials, with some studies investigating extended interval two-dose regimens, while others follow the standard three-dose schedule over 6 months.
  • What are some potential benefits being investigated in these trials? The trials are investigating potential benefits such as improved immune responses with extended dosing intervals, reduction in recurrence rates of HPV-related lesions after treatment, clearance of persistent HPV infections, and possible therapeutic effects on existing HPV-related conditions like warts and cervical lesions.

Ongoing Clinical Trials on Human Papillomavirus Type 58 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna

Glossary

  • HPV (Human Papillomavirus): A group of viruses that can cause various types of cancer and genital warts. There are many types of HPV, some of which are targeted by the 9-valent vaccine.
  • 9-valent HPV vaccine: A vaccine that protects against nine types of HPV (6, 11, 16, 18, 31, 33, 45, 52, and 58), also known as Gardasil 9.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Seroconversion: The development of detectable antibodies in the blood directed against an infectious agent, indicating an immune response.
  • CIN (Cervical Intraepithelial Neoplasia): Abnormal changes in the cells on the surface of the cervix that could potentially lead to cervical cancer if left untreated.
  • HSIL (High-grade Squamous Intraepithelial Lesion): A precancerous condition where abnormal cells are found on the surface of the cervix or vulva.
  • LEEP (Loop Electrosurgical Excision Procedure): A treatment that uses a thin wire loop electrode to remove abnormal tissue from the cervix.
  • Conization: A surgical procedure to remove a cone-shaped piece of tissue from the cervix for examination or treatment of abnormal cells.
  • Persistent infection: An infection that continues for an extended period, often defined as lasting more than 6-12 months in the context of HPV.
  • Recurrence: The return of a disease or condition after a period of improvement or remission.

References

  1. http://clinicaltrials.eu/trial-id/2022-500256-37-00
  2. http://clinicaltrials.eu/trial-id/2022-501413-31-00
  3. http://clinicaltrials.eu/trial-id/2022-501974-21-00
  4. http://clinicaltrials.eu/trial/study-on-hpv-vaccine-for-women-with-vulvar-hsil-evaluating-the-effectiveness-of-nonavalent-hpv-vaccine-in-preventing-recurrence-of-vulvar-high-grade-lesions/
  5. http://clinicaltrials.eu/trial/study-on-hpv-vaccine-after-treatment-for-high-grade-cervical-lesions-in-women-over-45/